How Orforglipron Affects Lipase

GLP-1 receptors are present in the pancreas, and GLP-1 agonists increase pancreatic enzyme output and acinar cell activity. The result is a rise in circulating lipase and amylase across the class, usually without inflammation. Rapid weight loss also raises the risk of gallstones, the most common cause of acute pancreatitis.

On the US label (pooled obesity trials): mean lipase +26 to +31% and pancreatic amylase +16 to +20% from baseline, versus +3 to +4% on placebo. The label states the clinical significance is unknown without symptoms.

Pancreatitis: listed as a warning (fatal and non-fatal haemorrhagic or necrotising pancreatitis has been seen with GLP-1 agonists). Gallbladder events: cholelithiasis 1% versus 0.7% on placebo, acute cholecystitis 0.4% versus 0.3%.

Class context: a pooled GLP-1 meta-analysis put the pancreatitis risk ratio at about 1.44, so a real but small increase.

Baseline: lipase before starting if you drink heavily, have high triglycerides, have had gallstones or pancreatitis, or are on a drug known to affect the pancreas.

During: do not chase asymptomatic lipase routinely. Check lipase urgently if you get severe upper abdominal pain, especially pain that goes through to your back, with or without vomiting.

Triglycerides: very high triglycerides cause pancreatitis on their own. Orforglipron lowers them, but steroids and GH can push them up, so keep a lipid panel on the schedule.

• Lipase above range with no pain: expected; recheck at your next routine bloods.
• Lipase above 3x the upper limit with abdominal pain: stop orforglipron and get seen the same day.
• Right upper abdominal pain, fever or yellowing: think gallbladder; stop and get assessed.
• Avoid heavy alcohol while titrating.

Australian availability and the full monitoring schedule: When will orforglipron be available in Australia?